The Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults1
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
GH treatment in adults with GH deficiency has numerous beneficial effects, but most studies have been small. We report the results of an Australian multicenter, randomized, double-blind, placebo-controlled trial of the effects of recombinant human GH treatment in adults with GH deficiency. GH deficiency was defined as a peak serum GH of < 5 mU/liter in response to insulin-induced hypoglycemia. Patients were randomly assigned to receive either GH (0.125 U/kg per week for 1 month and 0.25 U/kg per week for 5 months) or placebo. After 6 months, all patients received GH. The primary end points were biochemical responses, body composition, quality of life, and safety. One hundred sixty-six patients (72 females and 91 males) with a mean age of 40 +/- 1 yr (+/- SEM; range 17-67 yr) were recruited. Serum insulin-like growth factor-I (IGF-I) increased from a standard deviation score of -2.64 +/- 0.27 (range -8.8 +3.82; n = 78) to +1.08 +/- 2.87 (range -7.21 to +6.42) at 6 months in the GH/GH group; 38% of the whole group were above the age-specific reference range following treatment [17.6% and 68.9% with subnormal (< 2 SD) or normal (+/- 2 SD) pretreatment levels, respectively]. Fasting total cholesterol (P = 0.042) and low-density lipoprotein cholesterol (P = 0.006) decreased over the first 6 months. Fat-free mass increased in the first 6 months whether measured by bioelectrical impedance (P < 0.001) or dual energy x-ray absorptiometry (DEXA; P < 0.001). Total-body water increased in the first 6 months whether measured by bioelectrical impedance (P < 0.001) or deuterium dilution (P = 0.002). Fat mass measured by DEXA (P < 0.001), skinfold thicknesses (P < 0.001), and waist/hip ratio (P = 0.001) decreased in the first 6 months. Most changes in body composition were complete by 3 months of treatment and maintained to 12 months. Whole-body bone mineral density (BMD) (by DEXA) was unaffected by GH treatment. Self-reported quality of life was considered good before treatment, and beneficial treatment effects were observed for energy, pain, and emotional reaction as assessed by the Nottingham Health Profile. In the initial 6 months, adverse effects were reported by 84% of patients in the GH and 75% in the placebo group, with more symptoms relating to fluid retention in the GH group (48% vs. 30%; P = 0.016). Such symptoms were mild and resolved in 70% of patients despite continued treatment. Resting blood pressure did not change over the initial 6 months. In summary, GH treatment in adults with GH deficiency resulted in 1) prominent increases in serum IGF-I at the doses employed, in some cases to supraphysiological levels; 2) modest decreases in total- and low-density lipoprotein cholesterol, together with substantial reductions in total-body and truncal fat mass consistent with an improved cardiovascular risk profile; 3) substantial increases in lean tissue mass; and 4) modest improvements in perceived quality of life. The excessive IGF-I response and side-effect profile suggests that lower doses of GH may be a required for prolonged GH treatment in adults with severe GH deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Premature mortality due to cardiovascular disease in hypopituitarism
Rosén, T., & Bengtsson, B.-Å. (1990) · The Lancet · doi:10.1016/0140-6736(90)91812-o · Cited by 1,402
Validation of tetrapolar bioelectrical impedance method to assess human body composition
Lukaski, H. C., Bolonchuk, W. W., Hall, C. B., & Siders, W. A. (1986) · Journal of Applied Physiology · doi:10.1152/jappl.1986.60.4.1327 · Cited by 1,370
Salomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326
Self-citationRegional distribution of body fat, plasma lipoproteins, and cardiovascular disease.
Després, J. P., Moorjani, S., Lupien, P. J., Tremblay, A., Nadeau, A., & Bouchard, C. (1990) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.10.4.497 · Cited by 1,248
The growth hormone deficiency syndrome in adults
Cuneo, R. C., Salomon, F., McGauley, G. A., & Sönksen, P. H. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02347.x · Cited by 375
Self-citationQuality of Life of Adults with Growth Hormone Deficiency: a Controlled Study
BJORK, S., JONSSON, B., WESTPHAL, O., & LEVIN, J. ‐. (1989) · Acta Paediatrica · doi:10.1111/j.1651-2227.1989.tb11242.x · Cited by 135
Which adults develop side-effects of growth hormone replacement?
Holmes, S. J., & Shalet, S. M. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb01908.x · Cited by 101
Cited by
Giustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253
Serum levels of insulin-like growth factor I and its binding proteins in health and disease
Juul, A. (2003) · Growth Hormone & IGF Research · doi:10.1016/s1096-6374(03)00038-8 · Cited by 467
Maison, P., Griffin, S., Nicoue-Beglah, M., Haddad, N., Balkau, B., & Chanson, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030840 · Cited by 362
Growth Hormone Therapy in Adults and Children
Vance, M. L., & Mauras, N. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411607 · Cited by 269
Sesmilo, G., Biller, B. M. K., Llevadot, J., Hayden, D., Hanson, G., Rifai, N., & Klibanski, A. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-2-200007180-00010 · Cited by 257
Metadata
- Authors
- Cuneo, R. C., Judd, S., Wallace, J. D., Perry-Keene, D., Burger, H., Lim-Tio, S., Strauss, B., Stockigt, J., Topliss, D., Alford, F., Hew, L., Bode, H., Conway, A., Handelsman, D., Dunn, S., Boyages, S., Cheung, N. W., & Hurley, D.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1998-01
- Volume
- 83
- Issue
- 1
- Pages
- 107-116
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2140469927
- Cited by
- 245
- References
- 7
- FWCI
- 18.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.